JP2022090217A - 毛髪改善のための組成物 - Google Patents
毛髪改善のための組成物 Download PDFInfo
- Publication number
- JP2022090217A JP2022090217A JP2020202460A JP2020202460A JP2022090217A JP 2022090217 A JP2022090217 A JP 2022090217A JP 2020202460 A JP2020202460 A JP 2020202460A JP 2020202460 A JP2020202460 A JP 2020202460A JP 2022090217 A JP2022090217 A JP 2022090217A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- pioglitazone
- composition
- treatment
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 210000004209 hair Anatomy 0.000 title abstract description 54
- 230000006872 improvement Effects 0.000 title abstract description 5
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims abstract description 92
- 229960005095 pioglitazone Drugs 0.000 claims abstract description 46
- 230000003752 improving hair Effects 0.000 claims abstract description 10
- 238000011200 topical administration Methods 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 description 39
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000008859 change Effects 0.000 description 12
- 210000004761 scalp Anatomy 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000003648 hair appearance Effects 0.000 description 10
- 210000003128 head Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 238000003753 real-time PCR Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 5
- 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 5
- 101000983891 Homo sapiens Scavenger receptor cysteine-rich type 1 protein M130 Proteins 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000017423 tissue regeneration Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 102100025136 Macrosialin Human genes 0.000 description 4
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000010195 expression analysis Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 3
- 108010016731 PPAR gamma Proteins 0.000 description 3
- 230000001166 anti-perspirative effect Effects 0.000 description 3
- 239000003213 antiperspirant Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 210000004322 M2 macrophage Anatomy 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003690 classically activated macrophage Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003662 hair growth rate Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000013441 quality evaluation Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100273740 Mus musculus Cd68 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282576 Pan paniscus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- GFKPPJZEOXIRFX-UHFFFAOYSA-N TCA A Natural products CC(CCC(=O)O)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3 GFKPPJZEOXIRFX-UHFFFAOYSA-N 0.000 description 1
- ODMZDQKUHYGKKN-UHFFFAOYSA-N TCA C Natural products CC(CCCC(C)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3)C(=O)O ODMZDQKUHYGKKN-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- -1 cosmetologists Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000003873 peroxisome proliferator activated receptor gamma antagonist Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q9/00—Preparations for removing hair or for aiding hair removal
- A61Q9/04—Depilatories
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
(1)ピオグリタゾンを含む、毛髪の質の向上に用いるための組成物。
(2)経口投与用の組成物である、上記(1)に記載の組成物。
(3)皮膚への局所投与用の組成物である、上記(1)に記載の組成物。
できる。この態様において、医薬組成物は、懸濁されたピオグリタゾンを含み得る。ある態様では、医薬組成物は、溶解したピオグリタゾンを含み得る。ある態様では、医薬組成物は、ピオグリタゾンを含む懸濁液であり得る。ある態様では、医薬組成物は、ピオグリタゾンを含む、乳液、クリーム、またはオイルであり得る。
ピオグリタゾンとしては、ピオグリタゾン錠15mg「NP」を用いた。1錠のピオグリタゾンをすり鉢で粉砕し、3mLの注射用水PL「フソー」に懸濁して用いた。女性患者3人(69歳、48歳、65歳の患者)を対象とした。患者の両側の外眼角を頭側に延長し、両耳と頭頂を結ぶ線と交差する2点に墨汁で刺青をし、マーキングを中心に同一条件下で撮影した。頭皮のハーフサイド全体に対して、ピオグリタゾンの懸濁液を塗った。浸透性を高めるため、META-TDS, electroporation machine(CTP-802,Grand Aespio Inc., KOREA)を用いて3V/6mAの出力(実測値)で皮膚にピオグリタゾンを浸透させた。この処置を2週間おきに1度の頻度で12回(すなわち、6ヶ月間)行った。検査部位は、頭部の正中線から左右ともに51mm平均であった。治療開始から6カ月目(12回治療後)に、d
ermo prime, dpharris(CHOWIS, KOREA)を用いて各検査部位2枚をデジタル画像としてコンピュータに取り込み、毛髪の太いものから各画像3本(1検査画像2枚毛6本)を選別し、太さを自動計測した。その検査値(毛の太さ:mm)の平均値をもってグラフ化した。具体的には治療前を100として治療後の太さを割合で示した。ハーフサイド治療の患者群では治療前後と左右差を比較した。図1に示されるように、左右で比較すると、毛髪は、治療後1ヶ月(経過#1)、治療後6ヶ月(経過#6)と治療回数が増えて行くにつれてピオグリタゾン処置側(PG処置側)において、陰性対照と比較して毛髪が太くなることが確かめられた。また、図1下段には、未治療側の変化率に対する治療側の変化率を示す。図1下段に示されるように、PG処置側の変化率は陰性対照の変化率に比べて変化の割合が高いことが確かめられた。
本実施例では、髪のキューティクルについて処置前後で改善がみられたかを調べた。
5点:キューティクルが整っており、荒れが見当たらない。
4点:平均よりもキューティクルが整っているが、多少の荒れが認められる。
3点:キューティクルの整い方が平均的である。
2点:平均よりもキューティクルが荒れており、多少の剥がれが認められる。
1点:キューティクルが全体的に荒れており、全体的に剥がれが認められる。
次に、組織における遺伝子発現の変化を確認した。対象としては12週齢ウイスターラット(雄)を用いた。2.5μg/箇所投与群に関しては、背部に頭部から尾部に対して3つの領域を設定し、さらに各領域を背骨の左右で2つの領域に分けることで、背部に計6個の領域を設定した。これらの投与群では、この6個の各領域の中央付近の2箇所ずつにPGを投与した。具体的には、2.5μg/箇所投与群(n=3)に関しては、1箇所あたり2.5μg(20μL)のPGを投与した。また、0.1μg/箇所投与群および0.02μg/箇所投与群に関しては、頭部から尾部に対して2つの領域を設定し、さらに各領域を背骨の左右で2つの領域に分けることで、背部に計4個の領域を設定した。これらの投与群では、この4個の各領域の中央付近の2箇所ずつにPGを投与した。具体的には、0.1μg/箇所投与群(n=3)に関しては、1箇所あたり0.1μg(20μL)のPGを投与し、0.02μg/箇所投与群(n=2)に関しては、0.02μg(20μL)のPGを投与した。なお、前記2箇所間の距離は1cmとした。8週後に注入部中央上方を剃毛後3mmパンチで組織採取した。
1.) Ribosomal protein lateral stalk subunit P0 (RplP0), Rattus norvegicus: mRNA, 1,093 bp, NM_022402.2, GI: 310616731
Probe: 6-FAM/CCT GTC TTC /ZEN/CCT GGG CAT CAC G/3IABkFQ(配列番号1)
Primer-1: CAA TCC CTG ACG CAC CG(配列番号2)
Primer-2: TGT CTG CTC CCA CAA TGA AG(配列番号3)
2.) CD34, Rattus norvegicus: CD34 molecule (Cd34), mRNA 1,161 bp NM_001107202.2 GI: 169790781
Probe: 6-FAM/TCC CTG GAA /ZEN/GTA CCA GCC ACT ACT /3IABkFQ (配列番号4)
Primer-1: GGA GTA TTT CCA CCA GTT CCT AC(配列番号5)
Primer-2: GAT GGC TGG TGT GGT CTT ATT(配列番号6)
3.) Peroxisome proliferator-activated receptor gamma transcript variant 1, (PPARG), Rattus norvegicus: mRNA 1,805 bp NM_013124.3 GI: 223941861
Probe: 6-FAM/CCT GGG CGG /ZEN/TCT CCA CTG AGA ATA /3IABkFQ(配列番号7)
Primer-1: GAA TTA GAT GAC AGT GAC TTG GC(配列番号8)
Primer-2: AGC AGG TTG TCT TGG ATG TC(配列番号9)
4.) CD163 molecule (Cd163), Rattus norvegicus: mRNA 4,223 bp NM_001107887.1 GI: 157823808
Probe: 6-FAM/ACC CAA CGG /ZEN/CTT ACA GTT TCC TCA A/3IABkFQ/(配列番号10)
Primer-1: TCA TCC GTC TTC GAA TCC ATC(配列番号11)
Primer-2: TCT CAT TGC CTT CCT CTT GTG(配列番号12)
5.) CD68 molecule (Cd68), Rattus norvegicus: mRNA 1,224 bp NM_001031638.1 GI: 72255506
Probe: 6-FAM/CTC TGA TGT /ZEN/CGG TCC TGT TTG AAT CCA /3IABkFQ/(配列番号13)
Primer-1: TGA GAA TGT CCA CTG TGC TG(配列番号14)
Primer-2: CAT TCC CTT ACG GAC AGC TTA C(配列番号15)
1)Homo sapiens ribosomal protein lateral stalk subunit P0 (RPLP0), transcript variant 1, mRNA, 1,105 bp
Accession: NM_001002.4 GI: 1519314286
Probe: 56-FAM/CCC TGT CTT /ZEN/CCC TGG GCA TCA C/3IABkFQ/(配列番号16)
Primer-1: TGT CTG CTC CCA CAA TGA AAC(配列番号17)
Primer-2: TCG TCT TTA AAC CCT GCG TG(配列番号18)
2)Homo sapiens CD68 molecule (CD68), transcript variant 2, mRNA 1,790 bp
Accession: NM_001040059.1 GI: 91199549
Probe: 56-FAM/AGG TCC TGC /ZEN/ATG AAT CCA AAG CTG A/3IABkFQ/(配列番号19)
Primer-1: CCA TGT AGC TCA GGT AGA CAA C(配列番号20)
Primer-2: CCA CCT GCT TCT CTC ATT CC(配列番号21)
3)Homo sapiens CD163 molecule (CD163), transcript variant 1, mRNA 4,190 bp
Accession: NM_004244.5 GI: 344179109
Probe: 56-FAM/ATC CAT CTG /ZEN/AGC AGG TCA CTC CAG/3IABkFQ/(配列番号22)
Primer-1: CCA GAA CAC ATA TTC CCT CCA C(配列番号23)
Primer-2: GCA TAG TAA CTG TAC TCA CCA ACA(配列番号24)
4)Homo sapiens CD34 molecule (CD34), transcript variant 1, mRNA 2,621 bp
Accession: NM_001025109.1 GI: 68342037
Probe: 56-FAM/CCT TGC AAC /ZEN/ATC TCC CAC TAA ACC CT/3IABkFQ(配列番号25)
Primer-1: TGC CTG AAC ATT TGA TTT CTG C(配列番号26)
Primer-2: GAC CTT TCA ACC ACT AGC ACT(配列番号27)
ピオグリタゾンとしては、ピオグリタゾン錠15mg「NP」を用いた。患者は15mgのピオグリタゾンを含む錠剤1錠を午前10時前後に毎日1回服用した。患者4人(男性2人:54歳、56歳、女性2名:52歳、53歳の患者)を対象とした。患者の両側の外眼角を頭側に延長し、両耳と頭頂を結ぶ線と交差する2点に入れ墨をし、マーキングを中心に同一条件下で撮影した。
トリコグラムは、マーキングを中心に撮影(Canon Power Shot A520, Tokyo, Japan)し、撮影範囲に含まれる入れ墨を中心とした直径11mmの円(面積95mm2)内の毛髪を、2方向で写真撮影し、目視で計量し、その2枚の平均を得た。
Claims (3)
- ピオグリタゾンを含む、毛髪の質の向上に用いるための組成物。
- 経口投与用の組成物である、請求項1に記載の組成物。
- 皮膚への局所投与用の組成物である、請求項1に記載の組成物。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020202460A JP6925072B1 (ja) | 2020-12-07 | 2020-12-07 | 毛髪改善のための組成物 |
IL294882A IL294882A (en) | 2020-12-07 | 2021-12-03 | Preparations containing pioglisatone to improve hair |
CN202180025987.0A CN115361951B (zh) | 2020-12-07 | 2021-12-03 | 用于改善毛发的组合物 |
EP21903316.4A EP4260857A1 (en) | 2020-12-07 | 2021-12-03 | Composition for hair improvement |
MX2023006632A MX2023006632A (es) | 2020-12-07 | 2021-12-03 | Composicion para la mejora del cabello. |
KR1020237023152A KR20230116050A (ko) | 2020-12-07 | 2021-12-03 | 모발 개선을 위한 조성물 |
PCT/JP2021/044394 WO2022124212A1 (ja) | 2020-12-07 | 2021-12-03 | 毛髪改善のための組成物 |
JP2022568243A JPWO2022124212A1 (ja) | 2020-12-07 | 2021-12-03 | |
CA3204679A CA3204679A1 (en) | 2020-12-07 | 2021-12-03 | Composition for hair improvement |
US17/995,664 US20230181553A1 (en) | 2020-12-07 | 2021-12-03 | Composition for hair improvement |
AU2021395980A AU2021395980A1 (en) | 2020-12-07 | 2021-12-03 | Composition for hair improvement |
BR112023011258A BR112023011258A2 (pt) | 2020-12-07 | 2021-12-03 | Composição para melhoria do cabelo |
TW110145681A TW202237104A (zh) | 2020-12-07 | 2021-12-07 | 用於毛髮改善之組合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020202460A JP6925072B1 (ja) | 2020-12-07 | 2020-12-07 | 毛髪改善のための組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP6925072B1 JP6925072B1 (ja) | 2021-08-25 |
JP2022090217A true JP2022090217A (ja) | 2022-06-17 |
Family
ID=77364576
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020202460A Active JP6925072B1 (ja) | 2020-12-07 | 2020-12-07 | 毛髪改善のための組成物 |
JP2022568243A Pending JPWO2022124212A1 (ja) | 2020-12-07 | 2021-12-03 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022568243A Pending JPWO2022124212A1 (ja) | 2020-12-07 | 2021-12-03 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230181553A1 (ja) |
EP (1) | EP4260857A1 (ja) |
JP (2) | JP6925072B1 (ja) |
KR (1) | KR20230116050A (ja) |
CN (1) | CN115361951B (ja) |
AU (1) | AU2021395980A1 (ja) |
BR (1) | BR112023011258A2 (ja) |
CA (1) | CA3204679A1 (ja) |
IL (1) | IL294882A (ja) |
MX (1) | MX2023006632A (ja) |
TW (1) | TW202237104A (ja) |
WO (1) | WO2022124212A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090042909A1 (en) * | 2007-03-28 | 2009-02-12 | Pratima Karnik | Method of treating dermatological disorders |
JP2011530547A (ja) * | 2008-08-09 | 2011-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 化粧品としてのインドール化合物の使用 |
JP2012517969A (ja) * | 2009-02-16 | 2012-08-09 | ジュリアーニ インターナショナル リミテッド | 毛に関する状態を処置する方法 |
JP2020045302A (ja) * | 2018-09-18 | 2020-03-26 | 株式会社コンフェスタ | 角質軟化組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11406668B2 (en) | 2017-10-02 | 2022-08-09 | Hirotaro FUKUOKA | Pharmaceutical composition for use in improving quality of scalp or skin, wound healing, or improving quality of hair |
TWI787423B (zh) | 2017-12-26 | 2022-12-21 | 福岡大太朗 | 使用於增加毛髮、頭皮或皮膚之改質、創傷治癒、骨形成促進,或毛髮之改質的醫藥組成物 |
-
2020
- 2020-12-07 JP JP2020202460A patent/JP6925072B1/ja active Active
-
2021
- 2021-12-03 JP JP2022568243A patent/JPWO2022124212A1/ja active Pending
- 2021-12-03 BR BR112023011258A patent/BR112023011258A2/pt unknown
- 2021-12-03 EP EP21903316.4A patent/EP4260857A1/en active Pending
- 2021-12-03 MX MX2023006632A patent/MX2023006632A/es unknown
- 2021-12-03 US US17/995,664 patent/US20230181553A1/en active Pending
- 2021-12-03 AU AU2021395980A patent/AU2021395980A1/en active Pending
- 2021-12-03 IL IL294882A patent/IL294882A/en unknown
- 2021-12-03 WO PCT/JP2021/044394 patent/WO2022124212A1/ja unknown
- 2021-12-03 CA CA3204679A patent/CA3204679A1/en active Pending
- 2021-12-03 CN CN202180025987.0A patent/CN115361951B/zh active Active
- 2021-12-03 KR KR1020237023152A patent/KR20230116050A/ko active Search and Examination
- 2021-12-07 TW TW110145681A patent/TW202237104A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090042909A1 (en) * | 2007-03-28 | 2009-02-12 | Pratima Karnik | Method of treating dermatological disorders |
JP2011530547A (ja) * | 2008-08-09 | 2011-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 化粧品としてのインドール化合物の使用 |
JP2012517969A (ja) * | 2009-02-16 | 2012-08-09 | ジュリアーニ インターナショナル リミテッド | 毛に関する状態を処置する方法 |
JP2020045302A (ja) * | 2018-09-18 | 2020-03-26 | 株式会社コンフェスタ | 角質軟化組成物 |
Also Published As
Publication number | Publication date |
---|---|
BR112023011258A2 (pt) | 2023-10-31 |
EP4260857A1 (en) | 2023-10-18 |
TW202237104A (zh) | 2022-10-01 |
CN115361951A (zh) | 2022-11-18 |
MX2023006632A (es) | 2023-07-20 |
IL294882A (en) | 2022-09-01 |
CN115361951B (zh) | 2024-04-19 |
AU2021395980A1 (en) | 2023-07-06 |
US20230181553A1 (en) | 2023-06-15 |
JPWO2022124212A1 (ja) | 2022-06-16 |
WO2022124212A1 (ja) | 2022-06-16 |
CA3204679A1 (en) | 2022-06-16 |
JP6925072B1 (ja) | 2021-08-25 |
KR20230116050A (ko) | 2023-08-03 |
AU2021395980A9 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2498783B1 (en) | Compositions and methods for stimulating hair growth | |
JP7284316B2 (ja) | 皮膚美白活性を持つペプチド及びその用途 | |
US20050226821A1 (en) | Cosmetic formulations containing l-arginine oligomers | |
US8952060B2 (en) | Composition for preventing hair loss or for stimulating hair growth | |
US9303261B2 (en) | Composition for controlling chromogenesis including microRNA | |
US9101785B2 (en) | Use of 2,3-dihydroxypropyl dodecanoate for treating seborrhoea | |
JP2022500346A (ja) | 皮膚美白活性を持つペプチド及びその用途 | |
JP6925072B1 (ja) | 毛髪改善のための組成物 | |
FR2984129A1 (fr) | Utilisation de la proteine mmp-12 dans la prevention et/ou le traitement des etats pelliculaires du cuir chevelu | |
BR112021004550A2 (pt) | usos de inibidores de inibidor de ativador de plasminogênio 1 (pai-1) | |
BR112021004542A2 (pt) | inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos | |
TW200526222A (en) | Method of stimulating hair growth | |
FR2823671A1 (fr) | Composition dermatologique comprenant l'acide nicotinique ou un amide, et une base sphingoide | |
JP3342672B2 (ja) | 表皮肥厚抑制剤 | |
KR102233916B1 (ko) | Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물 | |
WO2022181786A1 (ja) | 育毛剤 | |
WO2022265052A1 (ja) | 育毛剤 | |
KR101910595B1 (ko) | 터티오펜 유도체를 함유하는 탈모치료 및 발모촉진용 조성물 | |
KR100789344B1 (ko) | 올리고뉴클레오타이드를 포함하는 피부 노화 방지제 | |
WO2021105695A1 (en) | New use of angiotensin ii receptor agonist | |
CN116916881A (zh) | 育毛剂 | |
CN113164356A (zh) | 用于增强皮肤屏障或用于保湿的包含脱氢枞酸的皮肤外用剂组合物 | |
JP2022178071A (ja) | 育毛用組成物、遺伝子の発現促進用組成物 | |
CN118159284A (zh) | 包含肉毒杆菌衍生肽的用于止痛的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210326 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210326 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20210401 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210506 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210525 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210617 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210629 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210727 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6925072 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |